Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010-2019)

被引：15

作者：

Carvalhaes, Cecilia G. ^{[1
]}

Sader, Helio S. ^{[1
]}

Streit, Jennifer M. ^{[1
]}

Castanheira, Mariana ^{[1
]}

Mendes, Rodrigo E. ^{[1
]}

机构：

[1] JMI Labs, North Liberty, IA 52317 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2022年 / 66卷 / 02期

关键词：

lipoglycopeptides; E; faecium; VRE; VanA; VanB; vancomycin resistance; daptomycin resistance; CARE-ASSOCIATED INFECTIONS; SINGLE-DOSE ORITAVANCIN; ACUTE BACTERIAL SKIN; METHICILLIN-RESISTANT; VANCOMYCIN; HOSPITALS;

D O I：

10.1128/AAC.01667-21

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Oritavancin displayed potent and stable activity (MIC90 range of 0.06 to 05 mg/L) over a 10-year period (2010 to 2019) against Gram-positive pathogens that cause bloodstream infections (BSI), including methicillin-resistant Staphylococcus aureus (MRSA) and resistant subsets of Enterococcus spp. Daptomycin and linezolid were also active against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus (VRE). Only oritavancin and linezolid remained active against Enterococcus faecium isolates displaying an elevated daptomycin MIC (i.e., 2 to 4 mg/L). Proportions of methicillin-resistant S. aureus and vancomycin-resistant Enterococcus within the respective S. aureus and enterococcal populations decreased over this period.

引用

页数：6

共 24 条

[1]

[Anonymous], M100 CLSI S

[2] Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model [J].